The landmark NICE-SUGAR trial demonstrated that intensive insulin therapy (targeting 81 - 108 mg/dL) increased mortality and severe hypoglycemia compared to conventional control (<180 mg/dL) in critically ill adults [6]. Subsequent analyses have confirmed that hypoglycemia is an independent predictor of death and neurological injury [7].

Recent data emphasizes glycemic variability (GV) as a key metric. High GV, measured by coefficient of variation, is associated with endothelial dysfunction and worse outcomes, even if mean glucose levels are acceptable [8][9]. A contemporary systematic review confirmed that glycemic variability is an independent predictor of ICU mortality across diverse patient populations [10].

Target Range: Maintain blood glucose between 140-180 mg/dL (7.8-10.0 mmol/L) for most hospitalized patients with severe infection [1].Monitoring Variability: Use point-of-care testing every 1 - 2 hours during insulin titration. Continuous Glucose Monitoring (CGM) is emerging as a useful tool to detect variability and minimize glycemic excursions [11].Avoid Hypoglycemia: Treat glucose <70 mg/dL immediately. Hypoglycemia is more dangerous than moderate hyperglycemia.Diabetic Foot Infections: In non-critical settings, aim for tighter control (HbA1c <7%) post-discharge to prevent recurrence, but avoid aggressive lowering during the acute inflammatory phase [12].

Acute Phase (Days 1-3):During the initial 72 hours, patients experience intense catabolism with anabolic resistance and endogenous energy production estimated at 500 - 1400 kcal/day [13][14]. Early full feeding during this phase adds to endogenous production, potentially causing overfeeding, suppressing protective autophagy, and increasing complications [13][14]. Stabilization & Recovery Phase (Day 4+): As hemodynamic stability improves and vasopressor requirements decrease, endogenous production declines and exogenous nutrition becomes essential [13][14].

Current ESPEN guidelines strongly recommend hypocaloric nutrition not exceeding 70% of energy expenditure (EE) during the first week of critical illness [14]. This is supported by the NUTRIREA-3 trial, which demonstrated that low calorie/protein feeding during the first 7 days in ventilated adults with shock resulted in faster readiness for discharge compared to standard feeding [15]. After day 3 - 4, energy delivery can be progressively increased to 80% - 100% of measured EE as the patient transitions to an anabolic metabolism [13][14]. Indirect calorimetry remains the gold standard for determining EE; predictive equations should be avoided when possible due to significant inaccuracy [14]. If indirect calorimetry is unavailable, oxygen consumption (VO₂) from a pulmonary arterial catheter or carbon dioxide production (VCO₂) from the ventilator can be utilized to calculate EE. In instances where neither indirect calorimetry, VO₂, nor VCO₂ can be secured, a weight-based equation (20 - 25 kcal/kg/day) may be used as a last resort to determine energy targets [14].

Recent evidence challenges the routine use of high-dose protein supplementation in critical illness. ESPEN 2023 recommends 1.3 g/kg/day of protein equivalents delivered progressively [14]. The EFFORT Protein and PRECISe trials demonstrated that higher protein dosing (targeting >2.0 g/kg/day) showed no overall mortality benefit and suggested potential harm, particularly in patients with acute kidney injury, alongside higher gastrointestinal intolerance and reduced health-related quality of life [16][17]. Mechanisms of potential harm include anabolic resistance, mitochondrial toxicity from high ammonia levels, and increased glucagon promoting amino acid catabolism [13][14].

ESPEN 2023 strongly recommends early enteral nutrition (EN) within 48 hours for patients whose gastrointestinal (GI) tract is functioning but oral intake is not possible, rather than delaying EN or initiating early parenteral nutrition (PN) [14]. EN preserves gut barrier function and reduces infectious complications. Continuous EN is preferred over bolus administration to reduce diarrhea [14].

However, in patients who are hemodynamically compromised, ASPEN guidelines advise withholding EN until full resuscitation is achieved, and the initiation of EN should be observed closely in those undergoing withdrawal of vasopressor support [18]. Furthermore, PN should be withheld for the first 7 days if EN is feasible, even if caloric targets are not met; PN may be initiated during the first week only when oral and EN are strictly contraindicated [13][14].

Immunonutritionand Metabolic Modulation: The type of nutrient utilized can significantly influence the metabolic response to stress (MRS). Specific substrates, such as omega-3 fatty acids, arginine, and glutamine, play distinct roles in modulating inflammation, promoting the production of specialized pro-resolving mediators (SPMs), and supporting immune function [13]. However, routine use of these supplements in medical sepsis or general ICU patients is not recommended due to inconsistent mortality benefits and potential harm in hemodynamically unstable subgroups [18].Micronutrients: High-dose antioxidant monotherapy (selenium, vitamin C, vitamin E) should not be administered without proven deficiency [14]. Vitamin D status can be determined in at-risk patients, but routine high-dose supplementation shows no mortality benefit [19].

Severe infection and critical illness induce profound gut dysfunction, characterized by stress-induced splanchnic vasoconstriction, epithelial hypoxia, and dysbiosis. This leads to a collapse of short-chain fatty acid (SCFA)-producing taxa, impairing epithelial nutrition and immunomodulation, and increasing the risk of bacterial translocation [13]. While routine probiotic or prebiotic supplementation is not currently recommended due to a lack of specific indications, preserving the gut microbiome is a critical component of host-directed therapy [13][14]. Early enteral nutrition is the primary strategy to maintain gut barrier integrity and prevent bacterial translocation [14]. Emerging gut-directed strategies under investigation include elemental or peptide-based formulas to reduce digestive workload, SCFAs such as butyrate for their anti-inflammatory effects, and targeted modulation of enterohormones like glucagon-like peptide-1 (GLP-1) to support enterocyte recovery [13].

Adjunctive corticosteroids are conditionally recommended for specific populations based on robust RCT evidence:

Septic Shock:The ADRENAL trial demonstrated that hydrocortisone speeds up the resolution of shock but has a modest or neutral effect on mortality [20]. Similarly, the APROCCHSS trial showed that hydrocortisone plus fludrocortisone reduced 90-day mortality in patients with septic shock requiring vasopressors [21]. Current guidelines recommend considering hydrocortisone (200 mg/day) for patients with refractory septic shock despite adequate fluid resuscitation and vasopressors [1].

Severe Community-Acquired Pneumonia (CAP): For adults with severe CAP requiring ICU admission and mechanical ventilation, adjunctive corticosteroids are recommended based on theCAPE COD randomized clinical trial, which demonstrated reduced mortality and respiratory failure [22]. This recommendation is further supported by systematic reviews and meta-analyses confirming benefit in this specific population [23][24]. Typical regimens involve hydrocortisone 200 mg/day for 5 - 7 days, tapered based on clinical response.

Intravenous Immunoglobulin (IVIG): Remains investigational for general sepsis. While retrospective database studies suggest potential impact on mortality and inflammatory status [25], and expert opinion acknowledges possible benefit in modulating immune response [26], no large-scale RCT has demonstrated definitive outcome improvement. IVIG is not routinely recommended outside of specific indications like toxic shock syndrome.

Human Albumin:Should be considered primarily as a resuscitation fluid in patients requiring substantial volume expansion, particularly those with hypoalbuminemia or septic shock [27]. Its role as an immunomodulatory or nutritional adjunct remains unproven, and it should not be used solely for these purposes.

Statins:There is no support for de novo statin initiation in general sepsis. While previous large randomized trials failed to show benefit from initiating them de novo in sepsis-associated acute respiratory distress syndrome [28], and recent systematic reviews indicate that statin use may be associated with reduced mortality in sepsis [29], these findings are largely observational. Continue statins if the patient was already taking them, but do not initiate specifically for infection treatment.

The Society of Critical Care Medicine recommends theABCDEF Bundle (Assess pain, Breathing trials, Choice of sedation, Delirium monitoring, Early mobility, Family engagement) to minimize iatrogenic harm. Bed rest leads to rapid muscle loss. Systematic reviews confirm that physical therapy in the ICU improves functional outcomes and may reduce delirium duration [30]. A landmark randomized trial demonstrated that early exercise in critically ill patients enhances short-term functional recovery [31]. Expert consensus guidelines have established clear safety criteria for active mobilization of mechanically ventilated patients [32].

However, clinicians should temper expectations regarding universal benefits. The recent TEAM randomized trial demonstrated heterogeneous effects of early mobilization on patient-cantered outcomes, with no significant improvement in physical function at hospital discharge compared to usual care in some cohorts [33]. Therefore, early mobilization should be individualized based on patient stability, baseline function, and ongoing clinical trajectory rather than applied uniformly.

- Daily Sedation Vacations:Perform Spontaneous Awakening Trials (SATs) daily.

-Delirium Screening:Use CAM-ICU or ICDSC tools daily. Treat underlying causes before using antipsychotics.

-Get Them Moving: Consult physical therapy early. Even passive range-of-motion exercises help prevent contractures in sedated patients, but intensity and timing should be tailored to individual patient response.

Figure 1The Host Optimization Bundle. Schematic representation of the multidisciplinary approach to managing severe infections. Beyond antimicrobial therapy and source control (central patient), optimal outcomes rely on four supporting pillars: Glycemic Control (maintaining 140 - 180 mg/dL with attention to glycemic variability), Nutritional Support (phased enteral feeding with protein prioritization), Immunomodulation (judicious use of adjunctive corticosteroids, IVIG, albumin, and statins), and Functional Rehabilitation (early mobility and delirium prevention). Implementation of this bundle requires coordinated care among infectious disease specialists, intensivists, endocrinologists, dietitians, and rehabilitation therapists.

Figure 1.The host optimization bundle.